GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

soralimixin   Click here for help

GtoPdb Ligand ID: 14372

Synonyms: BRII-693 | F365 | QPX9003
Compound class: Peptide
Comment: Soralimixin is a lipopeptide with activity against Gram-negative bacteria. It is a polymyxin analogue, rationally designed to overcome the clinical limitations of this class of antibacterial compounds [1].
Structure match for the INN soralimixin is included in WHO proposed list 134 (Feb 2026).
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CC(C)C)C(=O)N1)NC(=O)[C@H](CN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)C2=CC=C(C=C2Cl)Cl
Isomeric SMILES CC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N1)CC(C)C)CCN)NC(=O)[C@H](CN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)C2=C(C=C(C=C2)Cl)Cl)[C@@H](C)O)CCN)CCN
InChI InChI=1S/C48H80Cl2N16O13/c1-6-28-39(70)59-29(9-14-51)40(71)61-32(12-17-54)44(75)65-36(23(4)67)47(78)56-18-13-33(42(73)60-30(10-15-52)41(72)63-34(19-22(2)3)45(76)57-28)62-46(77)35(21-55)64-48(79)37(24(5)68)66-43(74)31(11-16-53)58-38(69)26-8-7-25(49)20-27(26)50/h7-8,20,22-24,28-37,67-68H,6,9-19,21,51-55H2,1-5H3,(H,56,78)(H,57,76)(H,58,69)(H,59,70)(H,60,73)(H,61,71)(H,62,77)(H,63,72)(H,64,79)(H,65,75)(H,66,74)/t23-,24-,28+,29+,30+,31+,32+,33+,34-,35+,36+,37+/m1/s1
InChI Key XRXBRIQKVLXFMJ-BCLXPCSMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Soralimixin is being developed by Brii Biosciences as an intravenous treatment for serious infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative bacteria. A Phase 1 clinical study (NCT04808414) to evaluate the safety, tolerability, and pharmacokinetics of soralimixin in healthy adults has been completed, with favourable results published in early 2025 [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04808414 SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers Phase 1 Interventional Qpex Biopharma, Inc. 2